CTIS2023-510173-34-00
Active, not recruiting
Phase 1
A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies - LTF-CL-001
ConditionsRelapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10051812Term: Small cell lymphocytic lymphoma Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025320Term: Lymphomas non-Hodgkin's B-cell Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Relapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory multiple myeloma
- Sponsor
- Galapagos
- Enrollment
- 300
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject must be able and willing to comply with the clinical study protocol (CSP) requirements and must sign and date the informed consent form (ICF) as approved by the Independent Ethics Committee (IEC) / Institutional Review Board (IRB), prior to any study\-related procedures., All subjects who have been treated with a GLPG CAR T\-cell therapy in a clinical trial or Managed Access Program.
Exclusion Criteria
- •There are no exclusion criteria for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 3.2ong-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patientsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-003518-15-ROCelltrion, Inc.216
Active, not recruiting
Phase 1
A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 4.2ong-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patientsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-003518-15-PLCelltrion, Inc.350
Active, not recruiting
Not Applicable
A Long-term Continuation Study of Patients With Infantile-Onset Pompe Disease WhoWere Previously Enrolled in Protocol AGLU01602Pompe disease or glycogenosis type IIMedDRA version: 6.1Level: HLTClassification code 10024579EUCTR2005-001629-27-ITGENZYME
Active, not recruiting
Not Applicable
A Long-term Continuation Study of Patients with Infantile-Onset Pompe Disease who were previously enrolled in Protocol AGLU01602Pompe disease is a rare metabolic muscle disease inherited in an autosomal recessive fashion. Pompe disease is caused by a deficiency of GAA, which is needed for the degradation of lysosomal glycogen. Pompe disease is characterized by organelle bound (lysosomal) accumulation of glycogen in many body tissues. In general, there is an inverse correlation between the amount of residual GAA activity in patients with Pompe disease and the severity of the disease.EUCTR2005-001629-27-DEGenzyme Europe BV17
Active, not recruiting
Not Applicable
Evaluation of the effects of chronic treatment with venlafaxine (150 mg) and pregabalin (200 mg) on emotional indices of anxiety and panic induced by breathing carbon dioxide.Generalised anxiety disorderMedDRA version: 9.1Level: LLTClassification code 10018075Term: Generalised anxiety disorderEUCTR2008-000971-15-GBniversity of Bristol54